22 results on '"Matsumoto, Morio"'
Search Results
2. Risk Factors for Central Nervous System (CNS) Relapse after Autologous Stem Cell Transplant (ASCT) in Diffuse Large B-Cell Lymphoma (DLBCL)
3. Stem Cell Mobilization with High-Dose VP-16 Is Not Associated with an Increased Risk of Secondary MDS/AML after Autologous Transplant Against Malignant Lymphoma
4. Prognostic Value of Chromosomal Abnormalities for Follicular Lymphoma in the Rituximab-Era
5. Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial
6. Retrospective Analysis of Prognostic Factors for Waldenström Macroglobulinemia: A Multicenter Cooperative Study in Japan
7. Phase 2 Study of Lenalidomide in Combination with Low-Dose Dexamethasone in Japanese Transplantation-Ineligible Newly-Diagnosed Multiple Myeloma Patients
8. Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma
9. Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy
10. BCL6 Dose Not Negatively Regulate DNA Damage Response Genes in Multiple Myeloma Cells
11. Soluble IL-2 Receptor α Is a More Sensitive Diagnostic Biomarker Than β2 Microglobulin and Predicts Survival in Follicular Lymphoma: Retrospective Analysis of 305 Cases
12. Possibility of Lenalidomide Therapy and Determination of Its Ideal Dose for Patients with Relapsed or Refractory Multiple Myeloma
13. The Polymorphisms of Base Excision Repair Genes Influence the Prognosis of Multiple Myeloma
14. Polymorphisms of IL-10, IL-17A, IL-17F and IL-18 Affect the Clinical Features of Multiple Myeloma in Japanese Patients
15. Dual functions of cell-autonomous and non–cell-autonomous ADAM10 activity in granulopoiesis
16. A Phase I/II Study of Bortezomib in Combination with Melphalan and Prednisolone in Japanese Patients with Newly Diagnosed Multiple Myeloma
17. Common Fragile Site Gene FRA16D WWOX (WW domain containing oxidoreductase) Is Frequently Altered in Plasma Cells of Multiple Myeloma and MGUS, Possibly Related to Disease Development
18. Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis
19. The Impact of Outcome and Hepatic Toxicity in HCV-Infected Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus CHOP Therapy; A Retrospective Multicenter Japanese Analysis.
20. Prognostic Importance of Soluble Form IL-2 Receptor á (sIL-2Rá) and Its Relationship with Surface Expression of IL-2Rá of Lymphoma Cell in Diffuse Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy: a Retrospective Analysis of 409 Cases.
21. Evaluation of Central Nervous System Recurrence of Intravascular Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy
22. Improved Survival of Intravascular Large B-Cell Lymphoma (IVLBCL) by Rituximab Containing Combination Chemotherapies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.